Mutations in Malaria Parasites in Iran
Author Information
Author(s): Zakeri Sedigheh, Afsharpad Mandana, Raeisi Ahmad, Djadid Navid Dinparast
Primary Institution: Malaria and Vector Research Group, Biotechnology Research Center, Institut Pasteur of Iran
Hypothesis
The study aims to assess the patterns and prevalence of resistance to chloroquine and sulphadoxine-pyrimethamine in Plasmodium falciparum in Iran.
Conclusion
Chloroquine should be withdrawn from the treatment strategy in Iran, while sulphadoxine-pyrimethamine may remain the treatment of choice for uncomplicated malaria.
Supporting Evidence
- All P. falciparum isolates carried the 108N mutation.
- 98.5% of patients carried both 108N and 59R mutations.
- The prevalence of pfdhps 437G mutation was 17% in Chabahar and 33% in Sarbaz.
- 98% of isolates carried the pfcrt 76T mutation.
- Eight distinct haplotypes were identified among the samples.
Takeaway
The study found that many malaria parasites in Iran are resistant to chloroquine, so doctors should stop using it, but they can still use another drug called sulphadoxine-pyrimethamine for treatment.
Methodology
The study used PCR/RFLP methods to genotype mutations in 206 Plasmodium falciparum isolates collected from patients in Iran.
Limitations
The study may not represent all regions of Iran as it focused on specific districts.
Participant Demographics
Participants included Iranian, Afghani, and Pakistani nationals aged from 1 to over 60 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website